A PYMNTS Company

US: Pfizer and Allergan $160 billion merger collapses

By  |  April 6, 2016

The Dublin-based Botox-maker Allergan announced early Wednesday it would abandon its mega-merger with US pharmaceutical giant Pfizer after new government regulations made the tax advantage of the cross-Atlantic deal more difficult to achieve.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The move is a huge victory for the Obama administration in its campaign against inversions, in which US-based companies buy or merge with smaller foreign firms and move their headquarters overseas to lower their tax bills. The Treasury Department released new regulations Monday to stem the tide of such inversions, and Pfizer and Allergan spent two days scrambling to determine whether their merger still made financial sense.

    The merger, the largest proposed inversion in history, was expected to lower the pharmaceutical giant’s tax rate significantly, from about 24 percent to 17 percent, and save the company about $35 billion in taxes. But the rules announced late Monday would have made those savings harder to obtain.

    In separate press releases, the companies called it a mutual decision, and Pfizer said it agreed to pay Allergan a $150 million breakup fee.

    Full content: NYTimes

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.